

**Table S1.** Studies included in the systematic review and descriptive data.

| Author, year                 | N patients | Country of study | Study type           | Mental disorder (diagnostic tool) | Mean age | % Female | N (%) Diabetes | N (%) Obesity | N (%) Epilepsy | N (%) Hypertension | N (%) Asthma | N (%) Respiratory disease | N (%) CKD | N (%) cerebrovascular diseases | N (%) Cardiovascular diseases | N (%) gastrointestinal diseases | N (%) cancer | N (%) Chronic liver disease |
|------------------------------|------------|------------------|----------------------|-----------------------------------|----------|----------|----------------|---------------|----------------|--------------------|--------------|---------------------------|-----------|--------------------------------|-------------------------------|---------------------------------|--------------|-----------------------------|
| Afridi, 2016 <sup>17</sup>   | 100        | Pakistan         | Cross-sectional      | Depression (ICD-10)               | 32.7     | 50       | 4 (4)          | 2 (2)         | 3 (3)          | 9 (9)              | 1 (1)        | NA                        | 2 (2)     | NA                             | NA                            | NA                              | NA           | NA                          |
| Bendayan, 2022 <sup>18</sup> | 13019      | UK               | Retrospective cohort | Schizophrenia (ICD-10)            | NA       | 46.4     | 2208 (16.9)    | NA            | 652 (5)        | 2070 (15.9)        | 1291 (9.9)   | NA                        | 179 (1.4) | 573 (4.4)                      | NA                            | NA                              | NA           | 20 (0.1)                    |
| Bendayan, 2022 <sup>18</sup> | 4481       | UK               | Retrospective cohort | Bipolar disorder (ICD-10)         | NA       | 46.4     | 478 (10.7)     | NA            | 147 (3.3)      | 467 (10.6)         | 431 (9.6)    | NA                        | 100 (2.2) | 155 (3.4)                      | NA                            | NA                              | NA           | 2 (0.04)                    |
| Chan, 2021 <sup>19</sup>     | 13945      | China            | Cohort               | Schizophrenia (ICD9-CM)           | 40.6     | 54.3     | 314 (2.2)      | NA            | NA             | NA                 | NA           | 188 (1.3)                 | 38 (0.3)  | NA                             | 285 (2)                       | 467 (3.3)                       | 158 (1.1)    | NA                          |

**Table S1.** Studies included in the systematic review and descriptive data.

|                                       |  |                        |      |      |             |             |          |             |           |           |          |           |           |           |           |           |
|---------------------------------------|--|------------------------|------|------|-------------|-------------|----------|-------------|-----------|-----------|----------|-----------|-----------|-----------|-----------|-----------|
| Filipic, 2018 <sup>20</sup>           | 1897 (1060 patients, 837 controls from the general population)<br>Croatia Cohort | Not specified          | 48   | 51.2 | 122 (11.5)  | 254 (23.9)  | NA       | 392 (36.9)  | 75 (7)    | NA        | 81 (7.6) | 26 (2.4)  | NA        | NA        | NA        | 18 (1.7)  |
| Fonseca deFreitas, 2022 <sup>21</sup> | 20800<br>UK Retrospective cohort   | Psychosis (ICD-10)     | NA   | 51.5 | 6687 (32.1) | 5438 (26.1) | NA       | 9481 (45.6) | 3119 (15) | 552 (2.6) | NA       | NA        | NA        | NA        | NA        | NA        |
| Gabilondo, 2017 <sup>22</sup>         | 232138 (7331 patients; 2248075 control from general population)<br>Spain Cohort  | Schizophrenia (ICD-10) | 48.6 | 39.5 | 845 (11.5)  | NA          | 55 (0.7) | 1235 (16.8) | 158 (2.1) | 342 (4.7) | 71 (0.9) | 154 (2.1) | 167 (2.3) | 526 (7.2) | 183 (2.5) | 206 (2.8) |

**Table S1.** Studies included in the systematic review and descriptive data.

|                                  |  |                        |       |      |           |           |    |           |    |             |    |    |             |              |             |    |
|----------------------------------|--|------------------------|-------|------|-----------|-----------|----|-----------|----|-------------|----|----|-------------|--------------|-------------|----|
| Jahrami, 2017 <sup>23</sup>      | 240 (120 patients ; 120 matched controls )<br>Bahrain<br>Case-control                        | Schizophrenia (ICD-10) | 41.69 | 50.9 | 37 (30.8) | 56 (46.7) | NA | 38 (31.7) | NA | NA          | NA | NA | 10 (8.3)    | NA           | NA          | NA |
| Kugathasan, 2019 A <sup>24</sup> | 5432821 (30210 patients ; 5402611 controls from the general population)<br>Denmark<br>Cohort | Schizophrenia (ICD-10) | 32.6  | 45   | NA        | NA        | NA | NA        | NA | 7973 (26.4) | NA | NA | 6973 (23.1) | 11620 (38.4) | 4457 (14.7) | NA |

**Table S1.** Studies included in the systematic review and descriptive data.

|                                |                                 |                           |   |       |      |    |    |    |           |    |             |    |    |             |             |    |    |
|--------------------------------|---------------------------------|---------------------------|---|-------|------|----|----|----|-----------|----|-------------|----|----|-------------|-------------|----|----|
| Kugathasan, 2019 <sup>25</sup> | Denmark<br>Retrospective cohort | Schizophrenia<br>(ICD-10) | 9775                                      | 45.9  | NA   | NA | NA | NA | NA        | NA | 3609 (36.9) | NA | NA | 2621 (26.8) | 1822 (18.6) | NA | NA |
| Lasic, 2014 <sup>26</sup>      | Croatia<br>Case-control         | Depression<br>(ICD-10)    | 186 (62 patients ; 124 matched controls ) | 54.95 | 40.7 | NA | NA | NA | 32 (51.6) | NA | NA          | NA | NA | NA          | NA          | NA | NA |
| Lasic, 2014 <sup>26</sup>      | Croatia<br>Case-control         | Schizophrenia<br>(ICD-10) | 186 (62 patients ; 124 matched controls ) | 42.09 | 44.8 | NA | NA | NA | 24 (38.7) | NA | NA          | NA | NA | NA          | NA          | NA | NA |

**Table S1.** Studies included in the systematic review and descriptive data.

|                              |  |                           |       |      |            |              |          |             |              |             |            |          |             |             |            |            |
|------------------------------|--|---------------------------|-------|------|------------|--------------|----------|-------------|--------------|-------------|------------|----------|-------------|-------------|------------|------------|
| Launders, 2022 <sup>27</sup> | 343625 (68798 matched controls)<br>UK Cohort | Not specified*            | 40.92 | 44.8 | 4897 (7.1) | 11490 (16.7) | NA       | 8696 (12.6) | 10581 (15.4) | 486 (0.7)   | 2046 (2.9) | 2105 (3) | 778 (1.1)   | 1317 (1.9)  | 2863 (4.1) | 1223 (1.8) |
| Ma, 2022 <sup>28</sup>       | 1924 UK Retrospective cohort                 | Not specified*            | 48.2  | 49   | 238 (12.4) | NA           | 75 (3.9) | 325 (16.9)  | 471 (24.5)   | 7 (0.3)     | 88 (4.6)   | 74 (3.8) | 24 (1.2)    | 24 (1.2)    | 82 (4.2)   | 57 (2.9)   |
| Mirza, 2021 <sup>29</sup>    | 10554 UK Cohort                              | Schizophrenia (ICD-10)    | NA    | 49.7 | NA         | NA           | NA       | NA          | NA           | 1522 (14.4) | NA         | NA       | 1670 (15.8) | 1379 (13.1) | 533 (5)    | NA         |
| Mirza, 2021 <sup>29</sup>    | 3379 UK Cohort                               | Bipolar disorder (ICD-10) | NA    | 47.8 | NA         | NA           | NA       | NA          | NA           | 490 (14.5)  | NA         | NA       | 389 (11.5)  | 433 (12.8)  | 182 (5.4)  | NA         |

**Table S1.** Studies included in the systematic review and descriptive data.

|                             |  |                              |      |      |           |    |         |            |            |           |          |          |           |           |           |          |
|-----------------------------|--|------------------------------|------|------|-----------|----|---------|------------|------------|-----------|----------|----------|-----------|-----------|-----------|----------|
| Oreski, 2012 <sup>30</sup>  | 192<br>Croatia<br>Retrospective cohort | Schizophrenia<br>(ICD-10)    | 39.5 | 47.8 | 8 (4.1)   | NA | 8 (4.1) | 11 (5.7)   | NA         | 8 (4.1)   | NA       | NA       | 14 (7.3)  | 21 (10.9) | 4 (2)     | NA       |
| Oreski, 2012 <sup>30</sup>  | 97<br>Croatia<br>Retrospective cohort  | Bipolar disorder<br>(ICD-10) | 49.8 | 44.5 | 9 (9.3)   | NA | 1 (1)   | 18 (18.5)  | NA         | 1 (1)     | NA       | NA       | 22 (22.7) | 16 (16.5) | 5 (5.1)   | NA       |
| Pati, 2020 <sup>31</sup>    | 500<br>India<br>Retrospective cohort   | Not specified*               | 39.8 | 44.5 | 59 (11.8) | NA | NA      | 91 (18.2)  | NA         | NA        | NA       | NA       | NA        | 56 (11.2) | 69 (13.8) | NA       |
| Razzano, 2014 <sup>32</sup> | 457<br>USA<br>Retrospective cohort     | Not specified*               | 46.5 | 47.8 | 96 (21)   | NA | NA      | 197 (43.1) | 127 (27.8) | 86 (18.8) | 33 (7.2) | 20 (4.3) | 79 (17.3) | NA        | 23 (5)    | 31 (6.8) |

**Table S1.** Studies included in the systematic review and descriptive data.

|                                       |  |                           |      |      |           |           |          |            |           |         |           |          |          |           |           |         |
|---------------------------------------|--|---------------------------|------|------|-----------|-----------|----------|------------|-----------|---------|-----------|----------|----------|-----------|-----------|---------|
| Simunovic Filipic, 2020 <sup>33</sup> | 1166 (329 patients, 837 controls from the general population)<br>Croatia<br>Case-control | Schizophrenia (ICD-10)    | NA   | 48.7 | 28 (8.5)  | 74 (22.5) | NA       | 72 (21.9)  | 18 (5.5)  | NA      | 20 (6.1)  | 7 (2.1)  | 5 (1.5)  | NA        | NA        | 2 (0.6) |
| Smith, 2013 <sup>34</sup>             | 1424378 (2582 patients; 1421796 non-bi-polar controls)<br>UK<br>Cross-sectional          | Bipolar disorder (ICD-10) | 54.5 | 50.9 | 218 (8.4) | NA        | 47 (1.8) | 462 (17.9) | 179 (6.9) | 5 (0.2) | 189 (7.3) | 89 (3.4) | 59 (2.3) | 237 (9.2) | 115 (4.4) | 6 (0.2) |

**Table S1.** Studies included in the systematic review and descriptive data.

|                              |   |                |      |      |            |             |          |            |           |    |           |           |    |    |          |    |
|------------------------------|---|----------------|------|------|------------|-------------|----------|------------|-----------|----|-----------|-----------|----|----|----------|----|
| Woodhead, 2014 <sup>35</sup> | 308643<br>(4346 patients<br>;<br>304297 controls with no severe mental illness) | Not specified* | 40.6 | 48.8 | 560 (12.9) | 1105 (25.4) | 74 (1.7) | 829 (19.1) | 270 (6.2) | NA | 212 (4.9) | 118 (2.7) | NA | NA | 76 (1.7) | NA |
|                              | UK<br>Retrospective cohort  |                |      |      |            |             |          |            |           |    |           |           |    |    |          |    |